Synergy Health in good condition

Synergy Health is on track to meet expectations for the full year after a strong half year which saw both revenue and profits rise.

Synergy Health is on track to meet expectations for the full year after a strong half year which saw both revenue and profits rise.

This was the upbeat message from the provider of sterilisation services to hospitals as it presented its interim results and the figures appear to support this.

Revenues for the six months ending September 30th were up 10.5% at £171.6m (2011: £155.3m), with pre-tax profits up 9.8% at £18.2m (2011: £16.6m).

Operating cashflow was up 18.9% at £43.3m (2011: £26.4m) and its interim dividend has increased 15.8% to 7.9p from 6.82p the same period the previous year.

Net debt increased by £6.8m to £180.3m, taking into account the partial funding of the SRI Surgical Express acquisition, payment of deferred consideration of £10.5m to the vendors of BeamOne, and net capital expenditure of £23.6m for new facilities in Costa Rica and France (2011: £27.6m).

Richard Steeves, Chief Executive of Synergy Health, said: "Despite the ongoing economic challenges, particularly in Europe, I am very pleased with the resilience of the group, and the progress that it continues to make.

"Our strategy of bringing forward investment in the United States has been well timed and will support our global growth objectives. The acquisition of SRI has given Synergy a real presence and management depth, opening up a number of new business development opportunities."

The company completed the acquisition of SRI in July of this year and said the integration and turnaround of the business is going well and is ahead of plan.

The firm said good cost control help to lift group operating margins by 0.6%.

It saw a solid first half with strong revenue growth in Asia & Africa and the Americas offsetting weaker growth in Europe & Middle East and UK & Ireland.

Consensus estimates for the full year ending March 31st 2013 are for pre-tax profits of £47.18m on revenues of £386.31m.

CM

Recommended

Britain’s ten most-hated shares – w/e 9 August
Stocks and shares

Britain’s ten most-hated shares – w/e 9 August

Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
10 Aug 2022
Aviva: One for income investors to tuck away
Share tips

Aviva: One for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
10 Aug 2022
Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares as of 5 August, providing an insight into how investors are thinking and where opportunities may lie.
9 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022